 7. In the absence of rapidly progressing disease and after discussion with the Principal Investigator PI, the interval from prior treatment to time of IMGN901 administration will be at least 2 weeks or at least 5 half-lives for cytotoxicnoncytotoxic agents. The half-life be based on published pharmacokinetic literature abstracts, manuscripts, investigator brochures, or drug-administration manuals and will be documented in the protocol eligibility document. 